Business Wire

Exclusive Networks Grows X-OD Reach to 9 European Markets to Introduce Complete Fortinet Security Fabric Portfolio on a Subscription Basis

Share

Exclusive Networks today unveiled the latest evolution of its X-OD platform with expansion into Germany, Spain, Belgium, Finland, Austria and Ireland. This coincides with the introduction of Fortinet to the X-OD portfolio offering, with the end-to-end availability of all Fortinet solutions through the Fortinet Security Fabric on a subscription basis – a unique channel proposition in global distribution.

X-OD is now available to partners in 9 European markets (France, UK and the Netherlands already launched) with aggressive plans to extend into all global regions later this year. Exclusive Networks is growing its subscription revenues 5x faster than traditional capex-based sales, with X-OD a significant driver in the acceleration of market evolution.

“Wherever we go with X-OD, it is growing fast – now in the Nordics, Iberia and DACH, and across Benelux, UK&I and France,” said Jesper Trolle, CEO of Exclusive Networks. “The global pandemic has undoubtedly accelerated digital transformation more generally, making this proposition even more relevant to business needs. Digital customer experience, big data insights and opex-based consumption are here to stay. And our roadmap is on track to extend the capabilities of X-OD beyond Europe and into every Exclusive operating territory.”

The enhanced opportunities made possible by X-OD are particularly relevant when it comes to key technologies such as SD-WAN and market segments such as MSSP. Customer organisations face the challenge of shifting from predominantly opex-based MPLS investments into a large-scale, capex-based network evolution to SD-WAN infrastructure. These issues are negated and opportunities unlocked by X-OD-enabled consumption models.

In the case of MSSP partners who ordinarily face investing upfront in the infrastructure capabilities to drive their own managed security services, X-OD enables them to buy technology in the same way they sell it. The sheer breadth, diversity of complementary nature of Fortinet’s portfolio also benefits from X-OD’s ability to ‘subscriptionise’ products and services into discreet packages, and even allow partners to bundle these with their own service wraps that are elegantly presented to customers as a single, easy-to-consume offering. Partners benefit yet further from X-OD’s fully digital customer experience and access to rich data insights that fuel upsell/cross-sell initiatives and targeted sales campaigns.

“Fortinet’s partnership with Exclusive Networks is geared to create exceptional value and opportunity for our partners and customers,” said Patrice Perche, Chief Revenue Officer & EVP Support at Fortinet. “With X-OD, Exclusive has engineered another genuinely innovative contribution to channel dynamics that aligns with how we see the world and how we want our partners to be enabled and supported. This represents significant benefits to all levels of our partner community, and ultimately provides our customers with new ways of consuming our market-defining products and services.”

“We see fantastic opportunities for the vendors who have committed to X-OD, and are very excited to introduce Fortinet and its extensive portfolio of solutions in these early stages of worldwide rollout,” added Jesper Trolle. “We are aligned with theirs and our other vendor partners’ visions for innovation, recurring revenue and market flexibility. Together we are empowering channel partners to make a fast, safe and simple transition to subscription-based consumption both for their customers and their own business models, allowing them to sell ‘everything as a service’.”

About X-OD

X-OD is an on-demand platform that brings together and enhances all of Exclusive Networks’ products and services in one, user-friendly place. The platform is the centre of a new digitalised technology distribution ecosystem that is connecting the full value chain, bringing vendors and resellers closer to their customers.

X-OD is pivotal in enabling the shift to the subscription business model. The platform is transforming capex to opex payments, enabling technology to be bought in the same way it is sold and consumed. It is this flexibility combined with on-demand functionality, speed and simplicity that makes X-OD so relevant in a ‘customer-first’ world. www.x-od.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jemma Lowman
exclusivegroup@wearecohesive.com
01291626200

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye